TITLE

Hep to hepatitis C

PUB. DATE
October 1997
SOURCE
CMAJ: Canadian Medical Association Journal;10/01/97, Vol. 157 Issue 7, p874
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
22951804

 

Related Articles

  • New Hope for Hepatitis C Patients.  // Primary Care Reports;Sep2013, Vol. 19 Issue 9, p18 

    The article focuses on the study regarding the efficacy of polymerase inhibitor sofosbuvir in treating hepatitis C (HEP-C).

  • New Hope for Hepatitis C Patients.  // Clinical Oncology Alert;Sep2013 Clincal Briefs, p18 

    The article offers information on polymerase inhibitor sofosbuvir which has showed high efficacy in both untreated and treatment failures of hepatitis C (HEP-C).

  • Be sure to test baby-boomers for hepatitis C.  // Clinical Advisor;Jul2012, Vol. 15 Issue 7, p21 

    The article announces the launch of the "I.D. Hep C" campaign by the American Gastroenterological Association (AGA) for educating and encouraging people to test for hepatitis C.

  • Ann Jesse tackles hepatitis C with a vengeance. Lusky, Mark; Lusky, Heather // ColoradoBiz;May2000, Vol. 27 Issue 5, p14 

    Features Ann Jesse and Hep C Connection, a hepatitis C network and support system in Denver, Colorado. How Jesse started her quest against hepatitis C; Patients with high risks of hepatitis C; Health consequence of untreated hepatitis C virus.

  • WaterFire Raises Awareness of Hep C.  // Rhode Island Medical Journal;Aug2014, Vol. 97 Issue 8, p48 

    The article reports on the WaterFire Lighting for RI Defeats Hep C event that was held on July 26, 2014 on World Hepatitis Day in Rhode Island to raise awareness towards hepatitis C infection.

  • Mylan launches generic sofosbuvir for treatment of hepatitis C.  // FRPT- Chemical Snapshot;5/10/2015, p14 

    The article announces the launch of the generic version of Hepatitis C drug sofosbuvir under the brand name MyHep by pharmaceutical company Mylan NV.

  • High cost burden of RA and hep C speciality drugs.  // PharmacoEconomics & Outcomes News;4/13/2013, Issue 676, p8 

    The article reports on two studies which found that the cost of rheumatoid arthritis (RA) and hepatitis C (hep C) speciality drugs now account for more than half of the total cost of care for patients with these conditions.

  • CVS Picks Gilead For H epatitis C Treatments. AMY REEVES // Investors Business Daily;1/6/2015, pA01 

    Monday brought a surprising turn to the twisting story of hepatitis C treatments, as pharmacy giant CVS Health said it will offer exclusive coverage for Gilead Sciences' hep C drugs.

  • How early is early enough?  // Gut;May2006, Vol. 55 Issue 5, p732 

    An abstract of the article "Early Monotherapy With Pegylated Interferon Alpha-2b for Acute Hepatitis C Infection: The HEP-NET Acute-II Study," by J. Wiegand, P. Buggisch and W. Boecher is presented.

  • Calendar of Courses, Symposiums, and Conferences.  // American Journal of Gastroenterology;Feb2012, Vol. 107 Issue 2, p330 

    A calendar of symposiums, conferences, and courses is presented which includes the Joint International Neurogastroenterology and Motility Meeting, the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep), and Abdominal Radiology Course 2012.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics